Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 485 DKK 1.57%
Market Cap: 98.3B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Other Current Liabilities
kr4.3B
CAGR 3-Years
49%
CAGR 5-Years
54%
CAGR 10-Years
18%
Zealand Pharma A/S
CSE:ZEAL
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Other Current Liabilities
€313.5m
CAGR 3-Years
112%
CAGR 5-Years
90%
CAGR 10-Years
41%
B
Bavarian Nordic A/S
CSE:BAVA
Other Current Liabilities
kr2B
CAGR 3-Years
193%
CAGR 5-Years
165%
CAGR 10-Years
30%
Bioporto A/S
CSE:BIOPOR
Other Current Liabilities
kr80k
CAGR 3-Years
-84%
CAGR 5-Years
-60%
CAGR 10-Years
-37%
Saniona AB
STO:SANION
Other Current Liabilities
kr1.9m
CAGR 3-Years
-50%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology
Economic Moat
Narrow

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 682.76 DKK
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Genmab A/S's Other Current Liabilities?
Other Current Liabilities
4.3B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Other Current Liabilities amounts to 4.3B DKK.

What is Genmab A/S's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
18%

Over the last year, the Other Current Liabilities growth was 123%. The average annual Other Current Liabilities growth rates for Genmab A/S have been 49% over the past three years , 54% over the past five years , and 18% over the past ten years .

Back to Top